1997 Fiscal Year Final Research Report Summary
Purification of a novel T cell-derived eosinophil chemotactic factor and its significance in allergic diseases
| Project/Area Number |
08670253
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Kagawa Medical University |
|---|
Principal Investigator |
HIRASHIMA Mitsuomi Kagawa Medical University, Medicine, Professor, 医学部, 教授 (70109700)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIDA Tomoko Kagawa Medical University, Medicine, Research Associate, 医学部, 助手 (10253270)
OKADA Hiroki Kagawa Medical University, University Hospital, Assistant Professor., 医学部・附属病院, 講師 (00243775)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Keywords | eosinophil / heterogeneity / eosinophilic pneumonia / chemotactic factor / bronchial asthma / atopic dermatitis / disease severity / differential diagnosis |
|---|
| Research Abstract |
Our established T cell line cells (STO-2) produce five eosinophil chemotactic factors (ECF) with different isoelectric point (pI-5, pI-6, pI-7, pI-8, and pI-9). They exhibit different biological functions in eosinophils. We have also found that most of them are different factors from the identified chemotactic factors such as eotaxin and RANTES.
We assessed chemotactic response of eosinophils to the above STO-2-derived ECF in patients with diseases characterized by eosinophilia as described below.
1.Eosinophil response differs according to the presence or absence of dermal symptom in Kimura's disease.
2.In atopic dermatitis, the response differs according to the presence of complications and disease severity.
3.The response in asthmatic patients differs according to the disease severity, especially in the requirement of steroid therapy.
4.In eosinophilic pneumonia, we can make differential diagnosis between acute and chronic eosinophilic pneumonia by the difference of the eosinophil response.
Now, we have succeeded cDNA cloning of one of STO-2-derived ECF,ECF-pI7 which is also produced from T cells during the specific antigenic stimulation. We have also found that the factor (ecalectin) is a variant of galectin-9 that is one of galactoside-binding lectins. We are now going to clarify the biological functions and the significance of ecalectin in human allergic diseases.
|
